<DOC>
	<DOCNO>NCT02204111</DOCNO>
	<brief_summary>The primary objective study compare quality life ( QoL ) patient suffer soft tissue sarcoma , receive multidimensional intervention receive standard treatment .</brief_summary>
	<brief_title>Patient Directed Intervention Improve Quality Life Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Diagnosis advance metastatic soft tissue sarcoma Treatment trabectedin inlabel prescription Age least 18 year ( inclusive ) first visit Patients life expectancy least 6 month The informed consent form must sign study specific test procedures do Confirmation subject 's health insurance coverage prior first visit Ability understand follow studyrelated instruction ECOG PS &gt; 2 Estimated life expectancy le 6 month Patients STS receive trabectedin Contraindications accord local SmPC YondelisÂ® Subject custody order authority court law Exclusion period study simultaneous participation clinical study Previous assignment treatment study Close affiliation investigator ( e.g . close relative ) person work study site Subject employee GWTTUD GmbH Pharma Mar S.A . Criteria opinion investigator preclude participation scientific reason , reason compliance , reason subject 's safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Palliative Treatment</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Patient Reported Outcome</keyword>
</DOC>